NIH R01 · 2025
Acquired Cross-Resistance through MYC Amplification in Small Cell Lung Cancer
PROJECT SUMMARY Small cell lung cancer (SCLC) afflicts more than 30,000 patients per year and is rapidly fatal in 94% of cases, with median survival of less than one year. Although untreated SCLC is highly responsive to first-line chemotherapy, benefit is temporary and following relapse, resistance often extends to a broad spectrum of DNA damaging agents. Furthermore, investigational therapies in clinical trials are often confounded by the same cross-resistance that hinders standard second-line agents. Although critically important, cross-resistance is difficult to study experimentally, as it requires a model system that faithfully reproduces clinical outcomes and is adequately powered to…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.